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Abstract
Background. Angiotensin-converting enzyme inhibitors
(ACEI) and angiotensin II type 1 receptor blockers
(ARB) decrease cardiovascular mortality and slow the pro-
gression of renal disease in non-transplant patients, but
their impact on kidney transplant outcome has not been
well established.
Methods. Patients receiving a renal allograft in Spain in
1990, 1994, 1998 and 2002 were considered for the pres-
ent study. Only adult (≥18 years) recipients of a single kid-
ney transplant functioning at the end of the first year were
considered. A total of 4842 patients with clinical data
about ACEI/ARB therapy were included.
Results. During the initial 2 years after transplant, ACEI/
ARB were less frequently used in the 1990 and 1994 co-
horts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and
45.1%, respectively; P < 0.001). During the first year, a
total of 1063 patients (22.8%) received ACEI/ARB treat-
ment, and graft survival (50.0% for treated patients and
51.4% for untreated, P = ns), death-censored graft survival
(60.6% versus 63.5%, P = ns) and patient survival (68.8%
versus 66.6%, P = ns) were not different. During the initial
2 years, 1472 patients (31.4%) received treatment with
ACEI/ARB, and graft survival tended to be higher in trea-
ted patients (54.4% and 50.9%, P = 0.063). Since there
was an interaction between ACEI/ARB treatment and year
of transplant, graft survival was analysed in each cohort.
Cox regression analysis including the propensity score
for ACEI/ARB treatment showed an association between
ACEI/ARB treatment and graft survival in the 2002 cohort
(relative risk 0.36 and 95% confidence interval 0.17–0.75,
P = 0.007). Death-censored graft survival (63.8% versus
63.1%, P = ns) and patient survival (68.1% and 66.5%,
P = ns) were not significantly different.
Conclusions. The use of ACEI/ARB during the initial
2 years after transplantation was associated with a better
graft survival, but this effect was only observed in the
2002 cohort.
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Introduction
Angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin II type 1 receptor blockers (ARB) decrease
cardiovascular mortality, reduce proteinuria and delay
progression to end-stage renal failure in native kidneys
[1–3]. Trials using ACEI or ARB in renal transplant re-
cipients to study their potential benefit on graft function
are limited, and until now there has been only one sys-
tematic review [4]. Taking into consideration the better un-
derstanding of the mechanisms leading to chronic renal
allograft dysfunction and the better understanding of
the systemic and intrarenal effects of ACEI/ARB [5], it
has been suggested that these medications may also pro-
long renal allograft survival [6–9]. However, these advan-
tages should be balanced with an increased prevalence of
side effects such as anaemia, decreased glomerular filtra-
tion rate and hyperkalaemia [4, 10] that may limit the
effectiveness of these drugs in the kidney transplant
population.
In the present study, we evaluate the association be-
tween ACEI/ARB treatment and graft and patient out-
come in patients transplanted in 1990, 1994, 1998 and
2002 in Spain.
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Study design
Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002
were considered for the present study. All Spanish adult transplant centres
were invited to participate, and only adult patients (≥18 years) receiving a
single kidney transplant that was functioning at the end of the first year
were considered. Patients receiving multi-organic or double transplants
were excluded. Last follow-up was on 31 December 2005.
Clinical variables
The following variables were evaluated at the time of surgery: source of
the organ (living or deceased donor), donation before or after cardiac
death, cause of donor death (trauma, stroke or others), age and gender
of the donor and the recipient, height and weight of the recipient, presence
of hepatitis B surface antigen and hepatitis C virus antibodies in the donor
and the recipient, aetiology of end-stage renal disease, time on dialysis,
last panel reactive antibodies (PRA), number of human leukocyte antigen
(HLA) mismatches and cold ischaemia and re-anastomosis times.
After surgery, the presence of delayed graft function and acute rejec-
tion were recorded. Immunosuppressive treatment at 1 year was described
on an intention-to-treat basis and classified into four major groups:
(i) cyclosporine-based not associated with mycophenolate mofetil,
(ii) cyclosporine-based associated with mycophenolate mofetil, (iii) ta-
crolimus-based treatment and (iv) other treatments.
At 3 months and yearly thereafter, serum creatinine, 24 h proteinuria,
serum fasting glucose and serum cholesterol and triglycerides were re-
corded. Treatment with antihypertensive drugs including ACEI or ARB
was also recorded.
Definition of variables
Total number of HLA mismatches was calculated as the addition of the
number of mismatches in the A, B and DR loci. Delayed graft function
was defined as haemodialysis requirements during the first week after sur-
gery once accelerated or hyperacute rejection, vascular complications and
urinary tract obstruction were ruled out. The diagnosis of acute rejection
was defined at each centre based on clinical and/or histological data.
This study was approved by the Ethics Committee of the Hospital Uni-
versitari de Bellvitge. Medical records review was performed according to
Spanish law with reference to clinical data confidentiality protection. A
blinded code was assigned to each participating hospital in order to take
the centre effect into consideration.
Statistics
Descriptive results are expressed as frequencies and percentages for cat-
egorical variables: median, 25th and 75th percentiles for skewed contin-
uous variables and mean ± standard deviation for normally distributed
continuous variables. These variables were compared in ACEI/ARB users
Table 1. Treatment with ACEI/ARB by year of transplantation
ACEI/ARB 1990 N (%) 1994 N (%) 1998 N (%) 2002 N (%) Overall N (%) P-value
c
At 3 months 49 (6.1) 64 (5.9) 114 (7.6) 240 (18.8) 467 (10.0) <0.001
At 1 year 78 (9.7) 148 (13.7) 324 (21.5) 447 (34.9) 997 (21.4) <0.001
At 2 year 101 (12.9) 225 (21.7) 451 (31.0) 529 (43.3) 1306 (29.0) <0.001
During first year
a 86 (10.,7) 164 (15.2) 341 (22.7) 472 (36.9) 1063 (22.8) <0.001
During second year
b 122 (15.1) 266 (24.6) 505 (33.5) 579 (45.1) 1472 (31.4) <0.001
aACEI/ARB in visit at 3 months and/or 1 year.
bACEI/ARB in visit at 3 months and/or 1 and/or 2 years.
cChi-square test.
Table 2. Baseline characteristics into ACEI/ARB use during the first year
Characteristics No ACEI/ARB N (%) ACEI/ARB N (%) P-value
Donor age (year) 41.6 (16.8) 43.1 (17.0) 0.023
Donor female gender 1287 (35.7) 364 (34.3) 0.387
Patient age (year), mean (SD) 46.2 (13.3) 47.6 (12.8) 0.010
Patient female gender 1389 (38.5) 334 (31.5) <0.001
Diabetes at transplantation 156 (4.6) 97 (9.3%) <0.001
Hepatitis C virus positive 502 (15.1) 104 (10.3) <0.001
Weight (kg), mean (SD) 65.8 (12) 68.5 (12.4) <0.001
HLA mismatches
0 1249 (35.7) 307 (29.5) <0.001
1 1977 (56.6) 593 (57.1) <0.001
2 270 (7.7) 139 (13.4) 0.001
Immunosuppression
Cyclosporine without mycophenolate mofetil 1834 (51.1) 342 (32.2) <0.001
Cyclosporine with mycophenolate mofetil 813 (22.6) 266 (25) <0.001
Tacrolimus based 639 (17.8) 332 (31.2) <0.001
Other treatments 304 (8.5) 123 (11.6) <0.001
Delayed graft function 1027 (30.2) 318 (32.1) 0.254
Acute rejection 1053 (29.2) 264 (24.8) 0.005
New onset diabetes after transplantation 193 (5.6) 57 (5.4) <0.001
Impaired glucose tolerance after transplant 624 (18) 219 (20.9)
Creatinine 1 year (mg/dl), mean (SD) 1.6 (0.7) 1.7 (0.7) 0.014
Proteinuria 1 year (g/day), mean (SD) 0.3 (0.8) 0.4 (1.0) <0.001
Cholesterol 1 year (mg/dl), mean (SD) 220.9 (45.9) 213.7 (45.8) 0.296
Triglycerides 1 year (mg/dl), mean (SD) 148.4 (71.5) 152.7 (74.6) <0.001
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t-test for ordinal or not normally distributed continuous data and Student’s
t-test for continuous normally distributed data.
Kaplan–Meier analysis was used to estimate overall graft survival,
death-censored graft survival and patient survival. Log rank test was em-
ployed to compare differences between groups.
Use of ACEI/ARB was analysed considering two different settings in
order to take into account the timing of the introduction of treatment: in-
troduction during the first year after transplantation and introduction dur-
ing the initial 2 years after transplantation. Since the mean follow-up in
the 2002 cohort was 3 years, no attempts were made to evaluate introduc-
tion of this treatment after 3 years or later.
Cox regression analysis adjusting for year of transplantation was em-
ployed to analyse the association between ACEI/ARB use and graft sur-
vival, death-censored graft survival and patient survival. Since this
analysis showed an interaction between year of transplant and ACEI/
ARB treatment, the effect of this treatment was analysed in each cohort
of patients separately. Multivariate backward Cox regression analysis was
performed to further evaluate the independent association of ACEI/ARB
and survival.
In order to take into consideration confounding by indication, a pro-
pensity score was calculated and introduced in all multivariate analysis.
The propensity score was calculated by a logistic regression considering
all clinical variables that were significantly different between patients
treated or not with ACEI/ARB. This analysis provides a probability score
of being treated with ACEI/ARB for each patient, and this score (ranging
from 0 to 1) was divided in quartiles and considered in the multivariate
Cox regression analysis.
Results
Patients
A total of 4842 patients were considered in the present
study and distributed in the 1990, 1994, 1998 and 2002
cohorts as 851, 1124, 1512 and 1355 patients, respectively.
In the 1990 and 1994 cohorts, ACEI/ARB were less fre-
quently used than in 1998 and 2002 (Table 1). Character-
istics of patients according to ACEI/ARB use during the
first and second years are summarized in Tables 2 and 3.
Survival and ACEI/ARB treatment during the first year
after transplant
The proportion of recipients receiving ACEI/ARB treat-
ment during the first year after transplantation increased
from 10.7% in the 1990 cohort to 39.9% in the 2002 co-
hort. During the first year of follow-up, a total of 1063 pa-
tients (22.8%) were treated with ACEI/ARB, and graft
survival was 51.4% for patients not receiving ACEI/ARB
and 50.5% for treated patients (P =n s ) .C o xr e g r e s s i o n
analysis adjusting for the year of transplant confirmed that
there was no association between ACEI/ARB use and graft
survival. However, there was a significant interaction be-
tween year of transplant and ACEI/ARB treatment (P =
0.046). For this reason, the effect of ACEI/ARB treatment
on graft survival was analysed in each cohort. A signifi-
cant difference was only observed in the 1994 cohort in
the univariate analysis (relative risk (RR): 0.74 and 95%
confidence interval (CI): 0.56–0.97; P = 0.03), but multi-
variate Cox regression analysis including the propensity
score for ACEI/ARB treatment did not confirm the associ-
ation between ACEI/ARB treatment and graft survival in
the 1994 cohort.
Death-censored graft survival was 63.5% for untreated
patients and 60.6% for treated patients (P = ns). Similarly,
patient survival was 66.6% and 68.8%, respectively
(P = ns).
Survival and ACEI/ARB during the initial 2 years after
transplant
The proportion of recipients receiving ACEI/ARB treat-
ment during the initial 2 years after transplantation in-
creased from 15.1% in the 1990 cohort to 45.1% in the
2002 cohort. During the initial 2 years after transplantation,
1472 patients (31.4%) received treatment with ACEI/ARB,
Table 3. Baseline characteristics into ACEI/ARB use during 2
st year
Characteristics no ACEI/ARB N (%) ACEI/ARB N (%) P-value
Donor age (year), mean (SD) 41.3 (16.9) 43.4 (16.8) <0.001
Donor female gender 1146 (35.7) 508 (34.5) 0.430
Patient age (year), mean (SD) 46.1 (13.4) 47.4 (12.7) 0.006
Patient female gender 1281 (39.9) 444 (30.2) <0.001
Diabetes at transplantation 135 (4.4) 119 (8.3) <0.001
Hepatitis C virus 459 (15.6) 149 (10.6) <0.001
Weight (kg), mean (SD) 65.4 (12.0) 68.5 (12.4) <0.001
HLA mismatches
0 1123 (36.2) 440 (30.5) <0.001
1 1746 (56.2) 829 (57.4) <0.001
2 236 (7.6) 174 (12.1) <0.001
Immunosuppression
CSA without MMF 1671 (52.3) 513 (34.9) <0.001
CSA with MMF 701 (21.9) 380 (25.8) <0.001
Tacrolimus based 554 (17.3) 420 (28.6) <0.001
Other treatments 270 (8.4) 158 (10.7) <0.001
Delayed graft function 916 (30.2) 437 (31.8) 0.264
Acute rejection 940 (29.3) 380 (25.8) 0.014
New onset diabetes after transplantation 161 (5.3) 89 (6.1) <0.001
Impaired glucose tolerance after transplant 549 (17.9) 294 (20.2) <0.001
Creatinine 1 year (mg/dl), mean (SD) 1.6 (0.7) 1.7 (0.7) 0.004
Proteinuria 1 year (g/day), mean (SD) 0.3 (0.8) 0.4 (0.9) <0.001
Cholesterol 1 year (mg/dl), mean (SD) 221.4 (46.0) 214.7.(45.6) 0.959
Triglycerides 1 year (mg/dl), mean (SD) 149.1 (72.2) 150.0 (72.6) 0.001
ACE inhibitors and ARB in renal transplantation ii23and graft survival was 50.9% for patients not treated
with ACEI/ARB and 54.4% for patients treated with
ACEI/ARB (P = 0.063). Cox regression analysis adjust-
ing for the year of transplant showed that there was no
association between ACEI/ARB use and graft survival.
However, there was a significant interaction between
year of transplant and ACEI/ARB treatment (P =
0.037). For this reason, the effect of ACEI/ARB on graft
survival was further analysed in each cohort of patients.
A lower risk of graft failure was observed in patients
transplanted in 2002 (relative risk: 0.46 and 95% CI
of 0.23–0.88; P = 0.020). Multivariate Cox regression
analysis including the propensity score for ACEI/ARB
treatment confirmed the association between ACEI/
ARB treatment and graft survival in the 2002 cohort
(Table 4).
Death-censoredgraftsurvivalwas63.1%for untreatedpa-
tients and 63.8% for treated patients (P = ns). Similarly, pa-
tient survival was 66.5% and 68.1%, respectively (P =n s ) .
Discussion
A significant proportion of kidney transplant recipients
have a reduced glomerular filtration rate and, accordingly,
an increased cardiovascular risk and increased probability
for renal function deterioration [11]. Different strategies
have been employed to slow the decline of renal function
including the adjustment of immunosuppression, treatment
of hypertension or treatment of lipid abnormalities [12,13].
The proven efficacy of treatment with ACEI/ARB on the
progression of native renal disease suggested that a similar
benefit may be observed in transplanted patients. Possible
renoprotective mechanisms of these medications include a
decrease in the systemic and intraglomerular blood pres-
sure, prevention of renal scarring, inhibition of AT II-me-
diated glomerulosclerosis and reduction of proteinuria
[5,14,15]. These expectations were sustained by a recent
report [7] showing that treatment with ACEI/ARB in
2,031 renal transplants performed between 1990 and
2003 in an Austrian centre was associated with a signifi-
cant improvement of long-term graft and patient survival.
However, the retrospective study conducted by Opelz et al.
[9] including 17 207 kidney recipients and 1744 heart
transplants failed to demonstrate an association between
ACEI/ARB treatment and transplant outcome. Recently,
Amara et al.[ 17] showed that the rate of decline of renal
function in patients with chronic allograft nephropathy and
severe renal impairment was not adversely affected by 1-
year lisinopril treatment, but there was no amelioration of
renal function deterioration rate.
In our study, we analysed patients treated with ACEI/
ARB during the first year or the first 2 years of follow-up
in comparison to patients not receiving renin–angiotensin
blockade. Analysis of patient and graft survival in patients
treated with ACEI/ARB during the first year did not show
any difference between groups. The proportion of recipi-
ents receiving ACEI/ARB during the first year after trans-
plantation increased from 10.7% in the 1990 cohort to
39.9% in the 2002 cohort, showing an important time-
dependent modification of the indication criteria for
ACEI/ARB in transplanted patients.
The evaluation of patients treated with ACEI/ARB dur-
ing the initial two years yielded similar results. There were
no differences in graft survival between treated or not trea-
ted patients in the analysis of all cohorts, but since there
was an interaction between treatment and year of trans-
plant, we further analysed each cohort separately. This
analysis showed a reduced risk of graft failure for treated
patients transplanted in 2002. Multivariate Cox regression
analysis including a propensity score confirmed this find-
ing. However, it is important to notice that there are limita-
tions in this observational, retrospective study. The
association between ACEI/ARB and outcome may be spu-
rious, since multiple comparisons were done and the asso-
ciation between treatment and outcome was relatively
weak. The advantage that in the 2002 cohort treated and
untreated patients were distributed in a similar proportion
may be overcome by the shorter follow-up of these pa-
tients. Thus, the potential benefit of ACEI/ARB on out-
come is a question that remains open and that can only
be answered by means of prospective randomized clinical
trials.
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